Isoform distinct time-, dose-, and castration-dependent alterations in flavin-containing monooxygenase expression in mouse liver after 2,3,7,8-tetrachlorodibenzo-p-dioxin treatment

Biochemical Pharmacology

Volumn 79, Issue 9, 2010, Pages 1345-1351

  Novick, Rachel M ^a   Vezina, Chad M ^a   Elfarra, Adnan A ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

2,3,7,8, Tetrachlorodibenzo p dioxin; Aryl hydrocarbon receptor; Castration; Flavin containing monooxygenase; Testosterone

Indexed keywords

2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; DIMETHYLANILINE MONOOXYGENASE; FLAVIN CONTAINING MONOOXYGENASE 1; FLAVIN CONTAINING MONOOXYGENASE 2; FLAVIN CONTAINING MONOOXYGENASE 3; FLAVIN CONTAINING MONOOXYGENASE 4; FLAVIN CONTAINING MONOOXYGENASE 5; LIVER ENZYME; MESSENGER RNA; METHIONINE S OXIDASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CASTRATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; EXPOSURE; GENE EXPRESSION; IMMUNOBLOTTING; LIVER; LIVER MICROSOME; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; ISOENZYMES; LIVER; MALE; MICE; ORCHIECTOMY; OXYGENASES; RNA, MESSENGER; TETRACHLORODIBENZODIOXIN;

EID: 77649193076     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.12.020     Document Type: Article

References (54)

1. Lawton M.P., Cashman J.R., Cresteil T., Dolphin C.T., Elfarra A.A., Hines R.N., et al. A nomenclature for the mammalian flavin-containing monooxygenase gene family based on amino acid sequence identities. Arch Biochem Biophys 308 (1994) 254-257
2. Hernandez D., Janmohamed A., Chandan P., Phillips I.R., and Shephard E.A. Organization and evolution of the flavin-containing monooxygenase genes of human and mouse: identification of novel gene and pseudogene clusters. Pharmacogenetics 14 (2004) 117-130
3. Phillips I.R., and Shephard E.A. Flavin-containing monooxygenases: mutations, disease and drug response. Trends Pharmacol Sci 29 (2008) 294-301
4. Krueger S.K., and Williams D.E. Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism. Pharmacol Ther 106 (2005) 357-387
5. Dixit A., and Roche T.E. Spectrophotometric assay of the flavin-containing monooxygenase and changes in its activity in female mouse liver with nutritional and diurnal conditions. Arch Biochem Biophys 233 (1984) 50-63
6. Falls J.G., Ryu D.Y., Cao Y., Levi P.E., and Hodgson E. Regulation of mouse liver flavin-containing monooxygenases 1 and 3 by sex steroids. Arch Biochem Biophys 342 (1997) 212-223
7. Coecke S., Debast G., Phillips I.R., Vercruysse A., Shephard E.A., and Rogiers V. Hormonal regulation of microsomal flavin-containing monooxygenase activity by sex steroids and growth hormone in co-cultured adult male rat hepatocytes. Biochem Pharmacol 56 (1998) 1047-1051
8. Chen Q.M., Alexander D., Sun H., Xie L., Lin Y., Terrand J., et al. Corticosteroids inhibit cell death induced by doxorubicin in cardiomyocytes: induction of antiapoptosis, antioxidant, and detoxification genes. Mol Pharmacol 67 (2005) 1861-1873
9. Ripp S.L., Itagaki K., Philpot R.M., and Elfarra A.A. Species and sex differences in expression of flavin-containing monooxygenase form 3 in liver and kidney microsomes. Drug Metab Dispos 27 (1999) 46-52
10. Lickteig A.J., Riley I.R., Melton R.J., Reitz B.A., Fischer H.D., and Stevens J.C. Expression and characterization of functional dog flavin-containing monooxygenase 3. Drug Metab Dispos 37 (2009) 1987-1990
11. Lemoine A., Williams D.E., Cresteil T., and Leroux J.P. Hormonal regulation of microsomal flavin-containing monooxygenase: tissue-dependent expression and substrate specificity. Mol Pharmacol 40 (1991) 211-217
12. Lattard V., Lachuer J., Buronfosse T., Garnier F., and Benoit E. Physiological factors affecting the expression of FMO1 and FMO3 in the rat liver and kidney. Biochem Pharmacol 63 (2002) 1453-1464
13. Lee M.Y., Clark J.E., and Williams D.E. Induction of flavin-containing monooxygenase (FMO B) in rabbit lung and kidney by sex steroids and glucocorticoids. Arch Biochem Biophys 302 (1993) 332-336
14. Miller M.M., James R.A., Richer J.K., Gordon D.F., Wood W.M., and Horwitz K.B. Progesterone regulated expression of flavin-containing monooxygenase 5 by the B-isoform of progesterone receptors: implications for tamoxifen carcinogenicity. J Clin Endocrinol Metab 82 (1997) 2956-2961
15. Zhang J., Chaluvadi M.R., Reddy R., Motika M.S., Richardson T.A., Cashman J.R., et al. Hepatic flavin-containing monooxygenase gene regulation in different mouse inflammation models. Drug Metab Dispos 37 (2009) 462-468
16. Wang T., Shankar K., Ronis M.J., and Mehendale H.M. Potentiation of thioacetamide liver injury in diabetic rats is due to induced CYP2E1. J Pharmacol Exp Ther 294 (2000) 473-479
17. Rae J.M., Johnson M.D., Lippman M.E., and Flockhart D.A. Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. J Pharmacol Exp Ther 299 (2001) 849-857
18. Park C.S., Baek H.M., Chung W.G., Lee K.H., Ryu S.D., and Cha Y.N. Suppression of flavin-containing monooxygenase by overproduced nitric oxide in rat liver. Mol Pharmacol 56 (1999) 507-514
19. Chung W.G., Park C.S., Roh H.K., and Cha Y.N. Induction of flavin-containing monooxygenase (FMO1) by a polycyclic aromatic hydrocarbon, 3-methylcholanthrene, in rat liver. Mol Cells 7 (1997) 738-741
20. Katchamart S., Stresser D.M., Dehal S.S., Kupfer D., and Williams D.E. Concurrent flavin-containing monooxygenase down-regulation and cytochrome P-450 induction by dietary indoles in rat: implications for drug-drug interaction. Drug Metab Dispos 28 (2000) 930-936
21. Patel R.D., Hollingshead B.D., Omiecinski C.J., and Perdew G.H. Aryl-hydrocarbon receptor activation regulates constitutive androstane receptor levels in murine and human liver. Hepatology 46 (2007) 209-218
22. Tijet N., Boutros P.C., Moffat I.D., Okey A.B., Tuomisto J., and Pohjanvirta R. Aryl hydrocarbon receptor regulates distinct dioxin-dependent and dioxin-independent gene batteries. Mol Pharmacol 69 (2006) 140-153
23. Ovando B.J., Vezina C.M., McGarrigle B.P., and Olson J.R. Hepatic gene downregulation following acute and subchronic exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicol Sci 94 (2006) 428-438
24. Hayes K.R., Zastrow G.M., Nukaya M., Pande K., Glover E., Maufort J.P., et al. Hepatic transcriptional networks induced by exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Chem Res Toxicol 20 (2007) 1573-1581
25. Whitlock Jr. J.P., Chichester C.H., Bedgood R.M., Okino S.T., Ko H.P., Ma Q., et al. Induction of drug-metabolizing enzymes by dioxin. Drug Metab Rev 29 (1997) 1107-1127
26. Celius T., Roblin S., Harper P.A., Matthews J., Boutros P.C., Pohjanvirta R., et al. Aryl hydrocarbon receptor (AHR)-dependent induction of flavin-containing monooxygenase mRNAs in mouse liver. Drug Metab Dispos 36 (2008) 2499-2505
27. Novick R.M., Mitzey A.M., Brownfield M.S., and Elfarra A.A. Differential localization of flavin-containing monooxygenase (FMO) isoforms 1, 3, and 4 in rat liver and kidney and evidence for expression of FMO4 in mouse, rat, and human liver and kidney microsomes. J Pharmacol Exp Ther 329 (2009) 1148-1155
28. Vezina C.M., Allgeier S.H., Fritz W.A., Moore R.W., Strerath M., Bushman W., et al. Retinoic acid induces prostatic bud formation. Dev Dyn 237 (2008) 1321-1333
29. Rozen S., and Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 132 (2000) 365-386
30. Lin T.M., Ko K., Moore R.W., Simanainen U., Oberley T.D., and Peterson R.E. Effects of aryl hydrocarbon receptor null mutation and in utero and lactational 2,3,7,8-tetrachlorodibenzo-p-dioxin exposure on prostate and seminal vesicle development in C57BL/6 mice. Toxicol Sci 68 (2002) 479-487
31. Sausen P.J., and Elfarra A.A. Cysteine conjugate S-oxidase. Characterization of a novel enzymatic activity in rat hepatic and renal microsomes. J Biol Chem 265 (1990) 6139-6145
32. Novick R.M., Elfarra A.A., and Purification. Characterization of flavin-containing monooxygenase isoform 3 from rat kidney microsomes. Drug Metab Dispos 36 (2008) 2468-2474
33. Boverhof D.R., Burgoon L.D., Tashiro C., Sharratt B., Chittim B., Harkema J.R., et al. Comparative toxicogenomic analysis of the hepatotoxic effects of TCDD in Sprague Dawley rats and C57BL/6 mice. Toxicol Sci 94 (2006) 398-416
34. Birnbaum L.S. Distribution and excretion of 2,3,7,8-tetrachlorodibenzo-p-dioxin in congenic strains of mice which differ at the Ah locus. Drug Metab Dispos 14 (1986) 34-40
35. Moore R.W., Potter C.L., Theobald H.M., Robinson J.A., and Peterson R.E. Androgenic deficiency in male rats treated with 2,3,7,8,-tetrachlorodibenzo-p-dioxin. Toxicol Appl Pharmacol 79 (1985) 99-111
36. Janmohamed A., Hernandez D., Phillips I.R., and Shephard E.A. Cell-, tissue-, sex- and developmental stage-specific expression of mouse flavin-containing monooxygenases (Fmos). Biochem Pharmacol 68 (2004) 73-83
37. Jana N.R., Sarkar S., Ishizuka M., Yonemoto J., Tohyama C., and Sone H. Cross-talk between 2,3,7,8-tetrachlorodibenzo-p-dioxin and testosterone signal transduction pathways in LNCaP prostate cancer cells. Biochem Biophys Res Commun 256 (1999) 462-468
38. Jana N.R., Sarkar S., Ishizuka M., Yonemoto J., Tohyama C., and Sone H. Comparative effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin on MCF-7, RL95-2, and LNCaP cells: role of target steroid hormones in cellular responsiveness to CYP1A1 induction. Mol Cell Biol Res Commun 4 (2000) 174-180
39. Barnes-Ellerbe S., Knudsen K.E., and Puga A. 2,3,7,8-Tetrachlorodibenzo-p-dioxin blocks androgen-dependent cell proliferation of LNCaP cells through modulation of pRB phosphorylation. Mol Pharmacol 66 (2004) 502-511
40. Sanada N., Gotoh Y., Shimazawa R., Klinge C.M., and Kizu R. Repression of activated aryl hydrocarbon receptor-induced transcriptional activation by 5alpha-dihydrotestosterone in human prostate cancer LNCaP and human breast cancer T47D cells. J Pharmacol Sci 109 (2009) 380-387
41. Ohtake F., Fujii-Kuriyama Y., and Kato S. AhR acts as an E3 ubiquitin ligase to modulate steroid receptor functions. Biochem Pharmacol 77 (2009) 474-484
42. Puga A., Ma C., and Marlowe J.L. The aryl hydrocarbon receptor cross-talks with multiple signal transduction pathways. Biochem Pharmacol 77 (2009) 713-722
43. Karoly E.D., and Rose R.L. Sequencing, expression, and characterization of cDNA expressed flavin-containing monooxygenase 2 from mouse. J Biochem Mol Toxicol 15 (2001) 300-308
44. Dolphin C.T., Beckett D.J., Janmohamed A., Cullingford T.E., Smith R.L., Shephard E.A., et al. The flavin-containing monooxygenase 2 gene (FMO2) of humans, but not of other primates, encodes a truncated, nonfunctional protein. J Biol Chem 273 (1998) 30599-30607
45. Whetstine J.R., Yueh M.F., McCarver D.G., Williams D.E., Park C.S., Kang J.H., et al. Ethnic differences in human flavin-containing monooxygenase 2 (FMO2) polymorphisms: detection of expressed protein in African-Americans. Toxicol Appl Pharmacol 168 (2000) 216-224
46. Krueger S.K., Williams D.E., Yueh M.F., Martin S.R., Hines R.N., Raucy J.L., et al. Genetic polymorphisms of flavin-containing monooxygenase (FMO). Drug Metab Rev 34 (2002) 523-532
47. Veeramah K.R., Thomas M.G., Weale M.E., Zeitlyn D., Tarekegn A., Bekele E., et al. Phillips IR The potentially deleterious functional variant flavin-containing monooxygenase 2*1 is at high frequency throughout sub-Saharan Africa. Pharmacogenet Genom 18 (2008) 877-886
48. Henderson M.C., Krueger S.K., Stevens J.F., and Williams D.E. Human flavin-containing monooxygenase form 2 S-oxygenation: sulfenic acid formation from thioureas and oxidation of glutathione. Chem Res Toxicol 17 (2004) 633-640
49. Francois A.A., Nishida C.R., de Montellano P.R., Phillips I.R., and Shephard E.A. Human flavin-containing monooxygenase 2. 1 Catalyzes oxygenation of the antitubercular drugs thiacetazone and ethionamide. Drug Metab Dispos 37 (2009) 178-186
50. Krause R.J., Ripp S.L., Sausen P.J., Overby L.H., Philpot R.M., and Elfarra A.A. Characterization of the methionine S-oxidase activity of rat liver and kidney microsomes: immunochemical and kinetic evidence for FMO3 being the major catalyst. Arch Biochem Biophys 333 (1996) 109-116
51. Ripp S.L., Overby L.H., Philpot R.M., and Elfarra A.A. Oxidation of cysteine S-conjugates by rabbit liver microsomes and cDNA-expressed flavin-containing mono-oxygenases: studies with S-(1,2-dichlorovinyl)-l-cysteine, S-(1,2,2-trichlorovinyl)-l-cysteine, S-allyl-l-cysteine, and S-benzyl-l-cysteine. Mol Pharmacol 51 (1997) 507-515
52. Overby L.H., Carver G.C., and Philpot R.M. Quantitation and kinetic properties of hepatic microsomal and recombinant flavin-containing monooxygenases 3 and 5 from humans. Chem Biol Interact 106 (1997) 29-45
53. Ripp S.L., Itagaki K., Philpot R.M., and Elfarra A.A. Methionine S-oxidation in human and rabbit liver microsomes: evidence for a high-affinity methionine S-oxidase activity that is distinct from flavin-containing monooxygenase 3. Arch Biochem Biophys 367 (1999) 322-332
54. Boutros P.C., Yan R., Moffat I.D., Pohjanvirta R., and Okey A.B. Transcriptomic responses to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in liver: comparison of rat and mouse. BMC Genom 9 (2008) 419